Frequency of positive thyroid peroxidase antibody levels in patients of generalized vitiligo
DOI:
https://doi.org/10.66344/jpad.v31i4.1758Abstract
Objective To determine the frequency of positive thyroid peroxidase antibodies in patients of generalized vitiligo.
Methods This cross sectional study was conducted in the Dermatology Unit 1 of Jinnah Hospital, Lahore for a period of six months. 125 cases of generalized vitiligo, of both genders, ages between 15-60 years, and with any duration of disease were enrolled.
Results A total of 125 cases of generalized vitiligo were enrolled. 61.6% (n=77) patients were between 15-30 years of age whereas 38.4 % (n=48) were between 31-60 years of age, Mean was calculated as 31.56±7.77 years, 56.8% (n=71) were male and 43.2% (n=54) were females. Frequency of positive thyroid peroxidase antibodies in patients of generalized vitiligo was recorded in 32.8% (n=41).
Conclusion The frequency of positive thyroid peroxidase antibodies is significant in patients of generalized vitiligo.
References
1. Dash R, Mohapatra A, Manjunathswamy B. Anti-thyroid peroxidase antibody in vitiligo: A prevalence study. J Thyroid Res.2015:8 available from:
www.Hindwai.com/journals/jtr/2015/192736.[accress 13th May 2016]
2. Gee N, Speechaest R. Acquired Pigmentary Disorders. In:Griffiths C, Barker J, Bleiker T, Chalmers R et al. Rook’s text book of Dermatology 9th edition. UK, John Wiley and sons;2016.p.88.31-88.33
3. Butt G, Altaf F, Wazir U, Pal S. Familial frequency of vitiligo and its association with autoimmune disorder. J Pak Assoc Dermatol.2015;15:101-4.
4. Daneshpayhook M, Mostofizadeh M, Behjati J, Akhyani M, Robati R. Antithyroid peroxidase and vitiligo: a controlled study. BMC Dermatol.2006;6:3. Available from: https://bmcdermatol.biomedcentral.com/articles/10.1186/1471-5945-6-3[Accessed 13th May 2018]
5. Kalami T, Ohtaki S. Thyroid peroxidase. Rinsho Byori.1990;38(4):442-5.
6. Khalil A, Zaidman I, Bergman R. Autoimmune complications after hematopoietic stem cell transplantation in children with nonmalignant disorders. Sci World J.2014;2014:581657.
7. EH Kemp. Autoantibodies a diagnostic and predictive marker of vitiligo. Autoimmunity. 2004;37(4):287-90.
8. Gey A, Diallo A, Seneschal J. Autoimmune thyroid disease in vitiligo: multivariate analysis indicates intricate pathomechanisms. Br J Dermatol.2013; 168:756.
9. Sheth VM, Guo Y, Qureshi AA. Comorbidities associated with vitiligo: a ten-year retrospective study. Dermatology. 2013;227:311.
10. Vrijman C, Kroon MW, Limpens J. The prevalence of thyroid disease in patients with vitiligo: a systematic review. Br J Dermatol.2012;167:1224.
11. Dogra S., Parsad D., Handa S., Kanwar A. J. Late onset vitiligo: a study of 182 patients. Int J Dermatol.2005;44(3):193–6.
doi: 10.1111/j.1365-4632.2004.01948.x.
12. Majumder P. P., Nordlund J. J., Nath S. K. Pattern of familial aggregation of vitiligo. Arch Dermatol.1993;129(8):994–8.
doi: 10.1001/archderm.129.8.994.
13. Daneshpazhooh M, Mostofizadeh G, Behjati J, Akhyani M, Robati RM. Anti-thyroid peroxidase antibody and vitiligo: a controlled study. BMC Dermatol.2006;6:3.
14. Mandry RC, Ortiz LJ, Lugo-Somolinos A, Sanchez JL. Organ-specific autoantibodies in vitiligo patients and their relatives. Int J Dermatol.1996;35:18-21.
15. Morgan M, Castells A, Ramirez A. Autoantibodies in vitiligo: clinical significance. Med Cutan Ibero Lat Am. 1986;14:139-42.
16. Dave S, D'Souza M, Thappa DM, Reddy KS, Bobby Z. High frequency of thyroid dysfunction in Indian patients with vitiligo. Indian J Dermatol.2003;48:68-72.
Downloads
Published
Issue
Section
License
Copyright (c) 2022 Ambreen Ashraf
This work is licensed under a Creative Commons Attribution 4.0 International License.
Submission declaration
Authors retain the copyright to their work and grant the 'Journal of Pakistan Association of Dermatologists (JPAD)' the right of first publication under a Creative Commons Attribution 4.0 International (CC BY 4.0) license. This license allows others to share, adapt, and reuse the work for any purpose, including commercial use, as long as appropriate credit is given to the original authors and the journal.
By submitting a manuscript, authors confirm that the work has not been published previously (except as an abstract, lecture, or academic thesis), is not under review elsewhere, and has been approved by all authors and relevant authorities. Once accepted, the article will be openly accessible under the CC BY 4.0 license, ensuring wide dissemination and reuse with proper attribution.
